Davis J. E. 4

4 · QUEST DIAGNOSTICS INC · Filed Nov 28, 2025

Form 4

Period: 2025-11-25

DirectorCEO and President

Transactions

Exercise/Conversion
Common Stock
2025-11-25$95.80/sh+55,093$5,277,634→ 175,573 total
Sale
Common Stock
2025-11-25$191.59/sh−9,342$1,789,823→ 166,231 total
Sale
Common Stock
2025-11-25$192.27/sh−41,004$7,883,901→ 125,227 total
Sale
Common Stock
2025-11-25$192.97/sh−4,747$916,037→ 120,480 total
Exercise/Conversion
Non-Qualifed Stock Option (right to buy)
2025-11-25$95.80/sh−55,093$5,277,634→ 0 total
Exercise: $95.80Exp: 2027-02-21→ Common Stock (55,093 underlying)

Footnotes (5)

[F1]This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
[F2]This transaction was executed in multiple trades at prices ranging from $190.810 to $191.805. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F3]This transaction was executed in multiple trades at prices ranging from $191.820 to $192.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]This transaction was executed in multiple trades at prices ranging from $192.820 to $193.310. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F5]The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.

Documents

1 file